— Research note —
KPV
Tripeptide C-terminal fragment of alpha-MSH investigated for anti-inflammatory activity in epithelial and mucosal research models.
KPV is the tripeptide lysine-proline-valine (Lys-Pro-Val), corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH itself is a 13-amino-acid post-translational product of proopiomelanocortin (POMC), and the tripeptide fragment has been studied since the 1990s as a minimal pharmacophore that retains a subset of the parent hormone's anti-inflammatory activities while lacking the pigmentary effects mediated by melanocortin-1 receptor activation at the melanocyte.
KPV has attracted interest because it appears to engage anti-inflammatory signaling through pathways that are at least partially independent of the canonical melanocortin receptors. Cellular uptake of the peptide via the PepT1 transporter has been documented in intestinal and colonic epithelial cells, providing a mechanism for direct intracellular access in mucosal tissues. Once intracellular, the peptide has been reported to inhibit nuclear factor-kappa B (NF-kB) translocation and reduce pro-inflammatory cytokine expression.
In preclinical research, KPV has been examined in murine models of colitis, where oral or rectal administration has been associated with attenuation of histological inflammation scores and reduction of inflammatory cytokine expression. Topical and inhaled formulations have been studied in dermatological and respiratory inflammation models. The peptide's small size, oral bioavailability, and apparent target selectivity have made it a useful tool compound for academic investigations of melanocortin-independent anti-inflammatory mechanisms.
The compound is supplied here for laboratory research use only and is not intended for human consumption. Its utility lies primarily in mechanistic studies of mucosal inflammation, epithelial peptide transport, and the structure-activity relationships of melanocortin-derived fragments.
Mechanism
KPV is internalized into epithelial cells primarily through the proton-coupled oligopeptide transporter PepT1, which is highly expressed in small intestinal and colonic epithelium and upregulated under inflammatory conditions. Once internalized, the tripeptide has been reported to interact with nuclear factor-kappa B signaling components, inhibiting IkappaB kinase activity and reducing NF-kB nuclear translocation in response to inflammatory stimuli.
Downstream effects include reduced expression of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 in stimulated epithelial preparations. KPV has also been reported to inhibit neutrophil chemotaxis and to attenuate mast cell degranulation in dermatological models. Unlike the parent alpha-MSH, the tripeptide shows limited activity at melanocortin receptors in standard binding assays, consistent with the observation that anti-inflammatory effects can be partly dissociated from melanocortin-1 receptor engagement.
Research history
The anti-inflammatory potential of alpha-MSH fragments has been recognized since the early 1990s, with the Catania and Lipton groups publishing extensively on the systemic anti-inflammatory properties of the parent hormone. KPV was identified as a minimal C-terminal pharmacophore in studies characterizing structure-activity relationships of melanocortin-derived anti-inflammatory peptides.
The Merlin laboratory at Emory and Georgia State Universities published a series of influential studies in the late 2000s and 2010s characterizing PepT1-mediated uptake of KPV in intestinal epithelium and demonstrating attenuation of colitis in murine DSS and TNBS models. These studies established KPV as a leading tool compound for academic investigations of mucosal inflammation.
Independent research has examined KPV in atopic dermatitis models, conjunctivitis preparations, and inhaled formulations for respiratory inflammation. Industry development has explored both oral and topical formulations of KPV and related minimal peptide pharmacophores, with limited progression to advanced clinical research. The tripeptide continues to appear as a reference compound in peer-reviewed studies of melanocortin-independent anti-inflammatory signaling and as a probe of PepT1-mediated peptide transport.
References
- Dalmasso G, et al. 2008. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PMID: 18166355
- Kannengiesser K, et al. 2008. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PMID: 18099355
- Brzoska T, et al. 2008. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev. PMID: 18348708
- Catania A, et al. 2004. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. PMID: 14709026
- Luger TA, et al. 1999. The role of alpha-MSH as a modulator of cutaneous inflammation. Ann N Y Acad Sci. PMID: 10593609
- Hiltz ME, Lipton JM. 1990. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J.
Do you have any questions about KPV?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.